Larvol Delta - Remibrutinib-Achieved-Higher-Rates-of-Complete-or-Partial-Response-Versus-Placebo-Phase-3-RemIND-Study

Rhapsido (remibrutinib) - Novartis

https://annualmeeting.acaai.org/2026/at_a_glance.cfm?session_key=379ADACD-C953-4C21-95B7-1B7846E5C0AF&session_date=Saturday,%20Nov%2014,%202026

Giselle S. Mosnaim, MD, MS, FACAAI

Sep 12, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next